Date: 2013-12-10
Type of
information: Initiation of the trial
phase: 1-2a
Announcement: initiation of a new pilot study
Company: Adaptimmune (UK)
Product: NYESO-1c259-T cell therapy product
Action
mechanism: cell therapy/gene therapy/immunotherapy product
Disease: multiple myeloma
Therapeutic
area: Cancer - Oncology
Country: USA
Trial
details:
- The trial is a Phase I/IIa, open label, multiple site clinical trial evaluating the safety and activity of engineered autologous T cells expressing an affinity-enhanced TCR Specific for NY-ESO-1 and LAGE-1 in patients with relapsed or progressive disease in multiple myeloma (NCT01892293). The primary objective of the study is to evaluate the safety and tolerability of autologous genetically modified T cells transduced to express the high affinity NY-ESO-1c259 TCR in HLA-A201 patients. Eligibility screening will be performed in two steps. First, patients will undergo prescreening to determine if they have the correct HLA type in order to respond to the engineered T cell therapy, and to test for presence of the target antigen, NY-ESO-1 and LAGE-1, in their tumor cells. Patients, who are HLA-A201 positive and test positive for expression of NY-ESO-1 and/or LAGE-1 in their myeloma tumor will move on to complete all screening procedures to determine eligibility for the study.
Patients will initially undergo a steady-state mononuclear cell apheresis for T cell collection. About 3-4 weeks later (to allow expansion engineering, releasing the engineered T cells), patients will receive a short course of cytoreductive chemotherapy prior to receiving the engineered T cell infusion, comprised of 1.5 gm/m2of cyclophosphamide, mesna will be given if in accordance with institutional standards. At day 0, patients will receive a dose of 0.1-1 x 1010 anti-CD3/anti-CD28-costimulated autologous T cells which have been genetically modified to express affinity-enhanced NY-ESO-1 T cell receptors (TCRs). A minimum dose of 0.1xPatients will undergo myeloma restaging approximately 1 week prior to the T cell infusion, and post infusion at days +28, +42 (week 6), +100 and 6 months post infusion and then every 3 months until relapse/progression or until 1 year, whenever comes first. At this point, patients will be followed semi-annually for up to 5 years and then annually for long term follow-up for monitoring for delayed adverse events until 15 years after receiving the genetically modified T cells, in accordance with FDA Guidelines.
Latest
news:
- • On December 10, 2013, Adaptimmune has announced that it has opened a new 10 patient pilot study, designed to evaluate the safety and anti-tumor effects of the engineered T cells without transplant. This trial is now enrolling at the University of Maryland in Baltimore, Maryland, and the City of Hope in Duarte, California.
The primary objective of the study is to evaluate the safety and tolerability of autologous genetically modified T cells transduced to express the high affinity NY-ESO-1c259 TCR in HLA-A201 patients. Eligibility screening will be performed in two steps. First, patients will undergo prescreening to determine if they have the correct HLA type in order to respond to the engineered T cell therapy, and to test for presence of the target antigen, NY-ESO-1 and LAGE-1, in their tumor cells. Patients, who are HLA-A201 positive and test positive for expression of NY-ESO-1 and/or LAGE-1 in their myeloma tumor will move on to complete all screening procedures to determine eligibility for the study.
Is
general: Yes
